FDA authorizes COVID-19 antibody test’s emergency use
The Food and Drug Administration Oct. 12 issued an emergency use authorization for Abbott Laboratories’ AdviseDx SARS-CoV-2 IgM (Immunoglobulin M) lab-based serology test.
Abbott said the test, which is used on its ARCHITECT and Alinity platforms, has demonstrated high reliability in its research and external virology laboratory studies, with 99.56% specificity and 95% sensitivity for patients tested 15 days after symptom onset.
Related News Articles
Headline
The Department of Health of Human Services Aug. 21 issued a request for information seeking feedback on immunization categories within the Aug. 10 executive…
Headline
For the 2025-2026 school year, exemptions from one or more vaccines among U.S. kindergartners was at 4.2%, increasing from 3.6% for the previous school year,…
Headline
A study published Aug. 5 by Nature found that COVID-19 infection can reactivate dormant, chronic viruses such as Epstein-Barr and cytomegalovirus. The study…
Headline
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…